TR 987
Alternative Names: Glucoprime; GLYC-101; MG-3601; TR-987Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Glycotex; Novogen
- Developer Glycotex; TR Therapeutics
- Class Anti-inflammatories; Glucans
- Mechanism of Action Dectin 1 stimulants; Macrophage stimulants; Toll-like receptor 2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Varicose ulcer
- No development reported Wounds
Most Recent Events
- 27 Nov 2024 Phase-III clinical trials in Varicose ulcer in USA (Topical), (NCT06707090),
- 11 Nov 2024 TR Therapeutics initiates phase III trial for Varicose ulcer in USA (Topical) (NCT06707103)
- 03 Sep 2021 Phase II development for Varicose ulcer is ongoing in USA (NCT03154619)